The Efficacy of Risk Factor Modification Compared to NAD+ Repletion in Diastolic Heart Failure.

Koay, YC; Liu, RP; McIntosh, B; Vigder, N; Lauren, S; Bai, AY; Tomita, S; Li, D; Harney, D; Hunter, B; Zhang, Y; Yang, J; Bannon, P; Philp, A; Philp, A; Kaye, DM; Larance, M; Lal, S; O'Sullivan, JF

The Efficacy of Risk Factor Modification Compared to NAD+ Repletion in Diastolic Heart Failure.

Koay, YC Liu, RP McIntosh, B Vigder, N Lauren, S Bai, AY Tomita, S Li, D Harney, D Hunter, B Zhang, Y Yang, J Bannon, P Philp, A Philp, A Kaye, DM Larance, M Lal, S O'Sullivan, JF

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: JACC Basic Transl Sci, 2024, 9, (6), pp. 733-750
Issue Date:: 2024-06

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (3.99 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Koay, YC
dc.contributor.author	Liu, RP
dc.contributor.author	McIntosh, B
dc.contributor.author	Vigder, N
dc.contributor.author	Lauren, S
dc.contributor.author	Bai, AY
dc.contributor.author	Tomita, S
dc.contributor.author	Li, D
dc.contributor.author	Harney, D
dc.contributor.author	Hunter, B
dc.contributor.author	Zhang, Y
dc.contributor.author	Yang, J
dc.contributor.author	Bannon, P
dc.contributor.author	Philp, A
dc.contributor.author	Philp, A
dc.contributor.author	Kaye, DM
dc.contributor.author	Larance, M
dc.contributor.author	Lal, S
dc.contributor.author	O'Sullivan, JF
dc.date.accessioned	2025-01-28T05:15:46Z
dc.date.available	2024-01-19
dc.date.available	2025-01-28T05:15:46Z
dc.date.issued	2024-06
dc.identifier.citation	JACC Basic Transl Sci, 2024, 9, (6), pp. 733-750
dc.identifier.issn	2452-302X
dc.identifier.issn	2452-302X
dc.identifier.uri	http://hdl.handle.net/10453/184297
dc.description.abstract	Heart failure (HF) with left ventricular diastolic dysfunction is a growing global concern. This study evaluated myocardial oxidized nicotinamide adenine dinucleotide (NAD+) levels in human systolic and diastolic HF and in a murine model of HF with preserved ejection fraction, exploring NAD+ repletion as therapy. We quantified myocardial NAD+ and nicotinamide phosphoribosyltransferase levels, assessing restoration with nicotinamide riboside (NR). Findings show significant NAD+ and nicotinamide phosphoribosyltransferase depletion in human diastolic HF myocardium, but NR successfully restored NAD+ levels. In murine HF with preserved ejection fraction, NR as preventive and therapeutic intervention improved metabolic and antioxidant profiles. This study underscores NAD+ repletion's potential in diastolic HF management.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	JACC Basic Transl Sci
dc.relation.isbasedon	10.1016/j.jacbts.2024.01.011
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.title	The Efficacy of Risk Factor Modification Compared to NAD+ Repletion in Diastolic Heart Failure.
dc.type	Journal Article
utslib.citation.volume	9
utslib.location.activity	United States
utslib.for	1102 Cardiorespiratory Medicine and Haematology
utslib.for	1103 Clinical Sciences
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2025-01-28T05:15:43Z
pubs.issue	6
pubs.publication-status	Published online
pubs.volume	9
utslib.citation.issue	6

Abstract:

Heart failure (HF) with left ventricular diastolic dysfunction is a growing global concern. This study evaluated myocardial oxidized nicotinamide adenine dinucleotide (NAD+) levels in human systolic and diastolic HF and in a murine model of HF with preserved ejection fraction, exploring NAD+ repletion as therapy. We quantified myocardial NAD+ and nicotinamide phosphoribosyltransferase levels, assessing restoration with nicotinamide riboside (NR). Findings show significant NAD+ and nicotinamide phosphoribosyltransferase depletion in human diastolic HF myocardium, but NR successfully restored NAD+ levels. In murine HF with preserved ejection fraction, NR as preventive and therapeutic intervention improved metabolic and antioxidant profiles. This study underscores NAD+ repletion's potential in diastolic HF management.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/184297